Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

Imatinib mesylate targets mutated KIT oncoproteins in gastrointestinal stromal tumor (GIST) and achieves a clinical response in 80% of patients. The mechanism is believed to depend predominantly on the inhibition of KIT-driven signals for tumor cell survival and proliferation. Using a mouse model of...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Balachandran, Vinod P., Cavnar, Michael J., Zeng, Shan, Bamboat, Zubin M., Ocuin, Lee M., Obaid, Hebroon, Sorenson, Eric C., Popow, Rachel, Ariyan, Charlotte, Rossi, Ferdinand, Besmer, Peter, Guo, Tianhua, Antonescu, Cristina R., Taguchi, Takahiro, Yuan, Jianda, Wolchok, Jedd D., Allison, James P., DeMatteo, Ronald P.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2011
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3278279/
https://ncbi.nlm.nih.gov/pubmed/21873989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.2438
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन